Zura Bio (NASDAQ:ZURA) Earns “Neutral” Rating from HC Wainwright

Zura Bio (NASDAQ:ZURA)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 115.52% from the stock’s previous close.

Several other research analysts have also commented on ZURA. Piper Sandler reiterated an “overweight” rating and set a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. Chardan Capital decreased their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Finally, Leerink Partners assumed coverage on Zura Bio in a research note on Monday, November 4th. They set an “outperform” rating and a $15.00 target price for the company. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $15.80.

Zura Bio Trading Down 2.5 %

ZURA stock opened at $2.32 on Tuesday. The firm has a 50-day moving average of $3.47 and a two-hundred day moving average of $3.66. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Sell-side analysts forecast that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Insider Activity at Zura Bio

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 22.10% of the company’s stock.

Institutional Trading of Zura Bio

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its stake in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after purchasing an additional 5,900 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after buying an additional 6,412 shares during the period. Forefront Analytics LLC grew its position in shares of Zura Bio by 22.1% during the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after buying an additional 7,531 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Zura Bio during the third quarter worth approximately $46,000. Finally, AQR Capital Management LLC acquired a new stake in Zura Bio in the second quarter valued at approximately $43,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.